1. Home
  2. CCCC

as 06-04-2025 1:32pm EST

$
-
.
-
-
+
$
-
.
-
-
+
-
.
-
-
%

Stocks

Health Care

Biotechnology: Pharmaceutical Preparations

Nasdaq

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients' lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. Its degrader medicines are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT1946, and CFT8919.

Founded: 2015 Country:
United States
United States
Employees: N/A City: WATERTOWN
Market Cap: 115.0M IPO Year: 2020
Target Price: $12.00 AVG Volume (30 days): 1.0M
Analyst Decision: Buy Number of Analysts: 3
Dividend Yield:
N/A
Dividend Payout Frequency: N/A
EPS: -1.48 EPS Growth: N/A
52 Week Low/High: $1.08 - $7.66 Next Earning Date: 07-31-2025
Revenue: $39,783,000 Revenue Growth: 98.56%
Revenue Growth (this year): -38.58% Revenue Growth (next year): -1.45%

CCCC Daily Stock ML Predictions

Share on Social Networks: